Curebound

Accelerating Cancer Cures

aka Padres Pedal the Cause | San Diego, CA | http://www.curebound.org

GuideStar Charity Check

Curebound

EIN: 46-0552414

Contributions tax deductible
as of November 2025

IRS BMF 509(a)(1)
as of November 14, 2025

View summary

Charity Check report

Mission

To mobilize San Diego to accelerate cancer cures in our lifetime.

Ruling year info

2014

CEO

Anne Marbarger

Main address

9605 Scranton Rd Ste 120

San Diego, CA 92121-1767 USA

Show more contact info

EIN

46-0552414

Subject area info

Cancers

Cycling

Philanthropy

Health care quality

Population served info

Adults

Terminally ill people

Chronically ill people

Children and youth

Caregivers

NTEE code info

Fund Raising and/or Fund Distribution (T12)

IRS subsection

501(c)(3) Public Charity

IRS filing requirement

This organization is required to file an IRS Form 990 or 990-EZ.

Tax forms

Show Forms 990

Communication

Programs and results

Reports and documents

What we aim to solve

SOURCE: Self-reported by organization

Curebound is a San Diego-based 501c3 philanthropic organization that raises and invests strategic funding in translational cancer research projects aimed at accelerating new discoveries to clinical application. Our mission - mobilize San Diego to accelerate cures for cancer in our lifetime. Our vision - a world without cancer.

Our programs

SOURCE: Self-reported by organization

What are the organization's current programs, how do they measure success, and who do the programs serve?

Discovery Grants

One-time seed grants of up to $250,000 for high-risk/ high-reward, translational research. Ideas are innovative and in the early phases where smaller grants can make a big impact in advancing research. Discovery Grants prioritize research that advances therapeutic development and/or has a high likelihood of leveraging extramural funding. Inter-institutional collaboration is required.

Targeted Grants

Larger gifts of $500,000 that aim to fund projects that are closer to clinical stages. Inaugural Targeted Grants require a clinical researcher to be part of the collaborative team in order to ensure the project is geared toward translational application. Priority is given to applications that have a high likelihood of significantly advancing detection, prevention, therapeutic development, access to patient care and/or clinical trials. Targeted Grants fund continuity of ideas from the investigators’ past research, including research that builds upon previously funded Discovery Grants. Interdisciplinary collaboration is required and inter-institutional collaboration, while not required, is preferred.

Cure Prize

Curebound’s highest award for bold innovation in cancer research. Cure Prizes are awarded to teams who present collaborative and/or interdisciplinary solutions that show near-term promise of clinical breakthrough and represent “game changers” in the prevention, diagnosis, access or treatment of cancer patients. Grant funding of $1,000,000+ is awarded and administered over a period of 2-3 years. The first Cure Prize challenge is to develop an innovation that will improve the standard of care for a typically deadly cancer with patient application in 3-5 years.

Population(s) Served

Adults

Caregivers

Chronically ill people

Terminally ill people

Children and youth

Where we work

San Diego (California, United States)
San Diego County (California, United States)

Awards

Small Nonprofit of the Year 2022

San Diego Business Journal

Champion of Health Equity Award 2024

California Life Sciences

Photos

Videos

Our results

SOURCE: Self-reported by organization

How does this organization measure their results? It's a hard question but an important one.

Total dollar amount of grants awarded

Totals By Year

Population(s) Served

Related Program

Type of Metric

Output - describing our activities and reach

Direction of Success

Increasing

Context Notes

Total Curebound cancer research grant funding

Goals & Strategy

SOURCE: Self-reported by organization

Learn about the organization's key goals, strategies, capabilities, and progress.

Charting impact

Four powerful questions that require reflection about what really matters - results.

What is the organization aiming to accomplish?

Curebound unites San Diego’s top research institutions in a collaborative effort to accelerate cancer research into cures. Founded upon a deeply held belief that cures are possible, we believe – and we are seeing – that the next decade will be critical to the development of sophisticated, individualized cancer treatment and the largest opportunity ever seen to advance the way we treat, and ultimately cure cancer. All of this is possible in San Diego.

San Diego is recognized as one of the largest and fastest growing life-science communities in the country and is uniquely positioned as a global center for cancer research, innovation and care. The city is home to three NCI-designated cancer centers, internationally recognized biotech research institutions, top clinical care hospitals and nearly 1,000 life-science companies that are taking cancer discoveries to clinical and commercial stages. Headquartered amongst this powerful scientific hub, Curebound is the catalyst to bring these resources together to drive this work faster and further- to expedite discovery and improve the lives of patients today.

What are the organization's key strategies for making this happen?

Collaboration is at the center of Curebound’s unique grantmaking platform. All Curebound grants demand collaboration among specialized teams from our research partner institutions, enabling the brightest minds from different scientific disciplines to work together to produce better options and outcomes for patients. Curebound research partners include:

- Moores Cancer Center at UC San Diego Health
- Salk Institute
- Sanford-Burnham Prebys
- Rady Children’s Hospital
- La Jolla Institute for Immunology
- Scripps Research

Curebound funds promising, innovative oncology research for all types of cancer, adult and pediatric, in alignment with five scientific investment pillars:

- Prevention and diagnostic tools
- Novel approaches and new therapeutic platforms
- Immunotherapies and personalized vaccines
- Cancer equities
- Pediatric cancers

What are the organization's capabilities for doing this?

What have they accomplished so far and what's next?

In 2021 two highly respected local cancer organizations, the Immunotherapy Foundation and Padres Pedal the Cause, united to form Curebound with an initial goal to raise and invest $100+ million into collaborative cancer research in San Diego. Over the last decade, these two organizations have collectively awarded over $23 million in funding for 90+ research grants that explore 20+ types of adult and pediatric cancers, including 6 pioneering clinical trials and major funding to initiate an Advanced Cell Therapy Lab and the San Diego Center for Precision Immunotherapy.

How we listen

SOURCE: Self-reported by organization

Seeking feedback from people served makes programs more responsive and effective. Here’s how this organization is listening.

We shared information about our current feedback practices.

How is your organization using feedback from the people you serve?

To identify and remedy poor client service experiences, To identify bright spots and enhance positive service experiences, To inform the development of new programs/projects, To strengthen relationships with the people we serve, To understand people's needs and how we can help them achieve their goals
Which of the following feedback practices does your organization routinely carry out?

We collect feedback from the people we serve at least annually, We aim to collect feedback from as many people we serve as possible, We take steps to ensure people feel comfortable being honest with us, We look for patterns in feedback based on people’s interactions with us (e.g., site, frequency of service, etc.), We engage the people who provide feedback in looking for ways we can improve in response, We act on the feedback we receive
What challenges does the organization face when collecting feedback?

It is difficult to get the people we serve to respond to requests for feedback

Financials

Curebound

Fiscal year: Jan 01 - Dec 31

Financial documents

Yes, financials were audited by an independent accountant.

Revenue vs. expenses: breakdown

SOURCE: IRS Form 990

NET GAIN/LOSS: in

Note: When component data are not available, the graph displays the total Revenue and/or Expense values.

Liquidity in 2023

SOURCE: IRS Form 990

2.20

Average of 1.99 over 10 years

Months of cash in 2023

SOURCE: IRS Form 990

13.1

Average of 9.9 over 10 years

Fringe rate in 2023

SOURCE: IRS Form 990

0%

Average of 11% over 10 years

Funding sources

Source: IRS Form 990

Assets & liabilities

Source: IRS Form 990

Financial data

SOURCE: IRS Form 990

Digitizing IRS form 990 data

Curebound

Revenue & expenses

Fiscal Year: Jan 01 - Dec 31

SOURCE: IRS Form 990 info

Fiscal year ending: Download Data

Revenue
Contributions	$2,352,836
Government Grants	$0
Program Services	$46,447
Investments	$1
Special Events	($25,604)
Sales	$0
Other	$0
Total Revenue	$2,373,680

Expenses
Program Services	$441,640
Administration	$187,287
Fundraising	$1,143,770
Total Expenses	$1,772,697
Net Gain/Loss	$600,983

Functional expenses
Accounting Fees	$22,577
Advertising & Promotion	$268,119
Information Technology Expenses	$42,502
Insurance Expenses	$7,846
Interest Expenses	$0
Investment Management Fees	$0
Legal Fees	$24,318
Pension Plan Contributions	$0
Professional Fundraising Expenses	$0

Revenue
Contributions	$1,928,086
Government Grants	$0
Program Services	$53,964
Investments	$118
Special Events	($24,701)
Sales	$0
Other	$0
Total Revenue	$1,957,467

Expenses
Program Services	$1,033,936
Administration	$199,586
Fundraising	$1,180,215
Total Expenses	$2,413,737
Net Gain/Loss	($456,270)

Functional expenses
Accounting Fees	$19,977
Advertising & Promotion	$161,443
Information Technology Expenses	$38,323
Insurance Expenses	$10,298
Interest Expenses	$0
Investment Management Fees	$0
Legal Fees	$1,119
Pension Plan Contributions	$0
Professional Fundraising Expenses	$0

Revenue
Contributions	$2,781,681
Government Grants	$0
Program Services	$64,570
Investments	$260
Special Events	($52,506)
Sales	$0
Other	$0
Total Revenue	$2,794,005

Expenses
Program Services	$1,425,869
Administration	$239,731
Fundraising	$1,062,421
Total Expenses	$2,728,021
Net Gain/Loss	$65,984

Functional expenses
Accounting Fees	$9,917
Advertising & Promotion	$2,776
Information Technology Expenses	$29,984
Insurance Expenses	$12,432
Interest Expenses	$1,529
Investment Management Fees	$0
Legal Fees	$365
Pension Plan Contributions	$0
Professional Fundraising Expenses	$0

Revenue
Contributions	$3,092,560
Government Grants	$0
Program Services	$150,770
Investments	$377
Special Events	($55,501)
Sales	$0
Other	$0
Total Revenue	$3,188,206

Expenses
Program Services	$2,126,971
Administration	$318,924
Fundraising	$830,329
Total Expenses	$3,276,224
Net Gain/Loss	($88,018)

Functional expenses
Accounting Fees	$27,197
Advertising & Promotion	$10,928
Information Technology Expenses	$29,759
Insurance Expenses	$12,053
Interest Expenses	$2,518
Investment Management Fees	$0
Legal Fees	$380
Pension Plan Contributions	$0
Professional Fundraising Expenses	$0

Revenue
Contributions	$3,576,806
Government Grants	$0
Program Services	$190,682
Investments	$435
Special Events	($88,169)
Sales	$0
Other	$0
Total Revenue	$3,679,754

Expenses
Program Services	$2,622,417
Administration	$190,264
Fundraising	$892,118
Total Expenses	$3,704,799
Net Gain/Loss	($25,045)

Functional expenses
Accounting Fees	$11,883
Advertising & Promotion	$51,202
Information Technology Expenses	$26,320
Insurance Expenses	$20,545
Interest Expenses	$0
Investment Management Fees	$0
Legal Fees	$190
Pension Plan Contributions	$0
Professional Fundraising Expenses	$0

Revenue
Contributions	$4,241,560
Government Grants	$0
Program Services	$237,307
Investments	$277
Special Events	($73,195)
Sales	$15,924
Other	$0
Total Revenue	$4,421,873

Expenses
Program Services	$3,225,911
Administration	$204,469
Fundraising	$940,343
Total Expenses	$4,370,723
Net Gain/Loss	$51,150

Functional expenses
Accounting Fees	$11,185
Advertising & Promotion	$92,555
Information Technology Expenses	$27,588
Insurance Expenses	$20,571
Interest Expenses	$0
Investment Management Fees	$0
Legal Fees	$452
Pension Plan Contributions	$0
Professional Fundraising Expenses	$0

Revenue
Contributions	$4,339,549
Government Grants	$0
Program Services	$281,605
Investments	$101
Special Events	($77,028)
Sales	$12,767
Other	$0
Total Revenue	$4,556,994

Expenses
Program Services	$3,403,693
Administration	$236,345
Fundraising	$985,546
Total Expenses	$4,625,584
Net Gain/Loss	($68,590)

Functional expenses
Accounting Fees	$13,670
Advertising & Promotion	$71,309
Information Technology Expenses	$26,248
Insurance Expenses	$21,288
Interest Expenses	$0
Investment Management Fees	$0
Legal Fees	$1,235
Pension Plan Contributions	$0
Professional Fundraising Expenses	$0

Revenue
Contributions	$1,362,861
Government Grants	$0
Program Services	$0
Investments	$52
Special Events	$0
Sales	$0
Other	$0
Total Revenue	$1,362,913

Expenses
Program Services	$236,830
Administration	$193,431
Fundraising	$441,805
Total Expenses	$872,066
Net Gain/Loss	$490,847

Functional expenses
Accounting Fees	$13,774
Advertising & Promotion	$9,323
Information Technology Expenses	$64,909
Insurance Expenses	$12,138
Interest Expenses	$0
Investment Management Fees	$0
Legal Fees	$421
Pension Plan Contributions	$8,189
Professional Fundraising Expenses	$0

Revenue
Contributions	$8,673,119
Government Grants	$76,995
Program Services	$76,935
Investments	$13
Special Events	($42,631)
Sales	$0
Other	$0
Total Revenue	$8,784,431

Expenses
Program Services	$1,912,366
Administration	$458,180
Fundraising	$463,059
Total Expenses	$2,833,605
Net Gain/Loss	$5,950,826

Functional expenses
Accounting Fees	$26,747
Advertising & Promotion	$207,102
Information Technology Expenses	$75,953
Insurance Expenses	$9,602
Interest Expenses	$17,997
Investment Management Fees	$0
Legal Fees	$8,631
Pension Plan Contributions	$0
Professional Fundraising Expenses	$0

Revenue
Contributions	$18,221,209
Government Grants	$0
Program Services	$2,931,116
Investments	$48
Special Events	($1,347,960)
Sales	$0
Other	$0
Total Revenue	$19,804,413

Expenses
Program Services	$4,643,589
Administration	$369,333
Fundraising	$1,216,147
Total Expenses	$6,229,069
Net Gain/Loss	$13,575,344

Functional expenses
Accounting Fees	$81,957
Advertising & Promotion	$150,712
Information Technology Expenses	$61,704
Insurance Expenses	$25,898
Interest Expenses	$0
Investment Management Fees	$0
Legal Fees	$28,864
Pension Plan Contributions	$0
Professional Fundraising Expenses	$0

Revenue
Contributions	$7,931,168
Government Grants	$0
Program Services	$0
Investments	$246,733
Special Events	$2,221,926
Sales	($4,299)
Other	$0
Total Revenue	$10,395,528

Expenses
Program Services	$9,887,172
Administration	$498,068
Fundraising	$2,115,102
Total Expenses	$12,500,342
Net Gain/Loss	($2,104,814)

Functional expenses
Accounting Fees	$149,427
Advertising & Promotion	$133,712
Information Technology Expenses	$116,860
Insurance Expenses	$47,513
Interest Expenses	$0
Investment Management Fees	$0
Legal Fees	$21,950
Pension Plan Contributions	$0
Professional Fundraising Expenses	$0

Curebound

Balance sheet

Fiscal Year: Jan 01 - Dec 31

SOURCE: IRS Form 990 info

The balance sheet gives a snapshot of the financial health of an organization at a particular point in time. An organization's total assets should generally exceed its total liabilities, or it cannot survive long, but the types of assets and liabilities must also be considered. For instance, an organization's current assets (cash, receivables, securities, etc.) should be sufficient to cover its current liabilities (payables, deferred revenue, current year loan, and note payments). Otherwise, the organization may face solvency problems. On the other hand, an organization whose cash and equivalents greatly exceed its current liabilities might not be putting its money to best use.

Fiscal year ending: Download Data

Assets	Jan 01, 2013	Dec 31, 2013	Change
Contributions	$2,352,836
Cash & Equivalents	$50,177	$282,030	$231,853
Accounts Receivable	$0	$0	$0
Pledges & Grants Receivable	$0	$655,000	$655,000
Receivable, Other	$0	$0	$0
Inventories for Sale or Use	$0	$0	$0
Investment, Securities	$0	$0	$0
Investment, Other	$0	$0	$0
Fixed Assets (LBE - Depreciation)	$0	$9,778	$9,778
Other	$4,791	$174,049	$169,258
Total Assets	$54,968	$1,120,857	$1,065,889

Liabilities	Jan 01, 2013	Dec 31, 2013	Change
Accounts Payable	$0	$464,906	$464,906
Grants Payable	$0	$0	$0
Deferred Revenue	$0	$0	$0
Loans and Notes	$0	$0	$0
Tax-Exempt Bond Liabilities	$0	$0	$0
Other	$0	$0	$0
Total Liabilities	$0	$464,906	$464,906

Fund balance	Jan 01, 2013	Dec 31, 2013	Change
Temporarily Restricted Net Assets	$0	$0	$0
Permanently Restricted Net Assets	$0	$0	$0
Total Restricted Net Assets	$0	$0	$0
Unrestricted Net Assets	$54,968	$655,951	$600,983
Net Assets	$54,968	$655,951	$600,983

Assets	Jan 01, 2014	Dec 31, 2014	Change
Contributions	$1,928,086
Cash & Equivalents	$282,030	$933,430	$651,400
Accounts Receivable	$0	$18,065	$18,065
Pledges & Grants Receivable	$655,000	$260,000	($395,000)
Receivable, Other	$0	$0	$0
Inventories for Sale or Use	$0	$0	$0
Investment, Securities	$0	$0	$0
Investment, Other	$0	$0	$0
Fixed Assets (LBE - Depreciation)	$9,778	$5,574	($4,204)
Other	$174,049	$32,612	($141,437)
Total Assets	$1,120,857	$1,249,681	$128,824

Liabilities	Jan 01, 2014	Dec 31, 2014	Change
Accounts Payable	$464,906	$1,050,000	$585,094
Grants Payable	$0	$0	$0
Deferred Revenue	$0	$0	$0
Loans and Notes	$0	$0	$0
Tax-Exempt Bond Liabilities	$0	$0	$0
Other	$0	$0	$0
Total Liabilities	$464,906	$1,050,000	$585,094

Fund balance	Jan 01, 2014	Dec 31, 2014	Change
Temporarily Restricted Net Assets	$0	$260,000	$260,000
Permanently Restricted Net Assets	$0	$0	$0
Total Restricted Net Assets	$0	$260,000	$260,000
Unrestricted Net Assets	$655,951	($60,319)	($716,270)
Net Assets	$655,951	$199,681	($456,270)

Assets	Jan 01, 2015	Dec 31, 2015	Change
Contributions	$2,781,681
Cash & Equivalents	$933,430	$1,517,757	$584,327
Accounts Receivable	$18,065	$0	($18,065)
Pledges & Grants Receivable	$260,000	$160,038	($99,962)
Receivable, Other	$0	$0	$0
Inventories for Sale or Use	$0	$0	$0
Investment, Securities	$0	$0	$0
Investment, Other	$0	$0	$0
Fixed Assets (LBE - Depreciation)	$5,574	$6,286	$712
Other	$32,612	$20,739	($11,873)
Total Assets	$1,249,681	$1,704,820	$455,139

Liabilities	Jan 01, 2015	Dec 31, 2015	Change
Accounts Payable	$1,050,000	$1,308,675	$258,675
Grants Payable	$0	$0	$0
Deferred Revenue	$0	$0	$0
Loans and Notes	$0	$0	$0
Tax-Exempt Bond Liabilities	$0	$0	$0
Other	$0	$0	$0
Total Liabilities	$1,050,000	$1,308,675	$258,675

Fund balance	Jan 01, 2015	Dec 31, 2015	Change
Temporarily Restricted Net Assets	$260,000	$0	-$260,000
Permanently Restricted Net Assets	$0	$0	$0
Total Restricted Net Assets	$260,000	$0	($260,000)
Unrestricted Net Assets	($60,319)	$396,145	$456,464
Net Assets	$199,681	$396,145	$196,464

Assets	Jan 01, 2016	Dec 31, 2016	Change
Contributions	$3,092,560
Cash & Equivalents	$1,517,757	$2,168,974	$651,217
Accounts Receivable	$0	$0	$0
Pledges & Grants Receivable	$160,038	$262,064	$102,026
Receivable, Other	$0	$0	$0
Inventories for Sale or Use	$0	$0	$0
Investment, Securities	$0	$0	$0
Investment, Other	$0	$0	$0
Fixed Assets (LBE - Depreciation)	$6,286	$0	($6,286)
Other	$20,739	$17,112	($3,627)
Total Assets	$1,704,820	$2,448,150	$743,330

Liabilities	Jan 01, 2016	Dec 31, 2016	Change
Accounts Payable	$1,308,675	$2,140,023	$831,348
Grants Payable	$0	$0	$0
Deferred Revenue	$0	$0	$0
Loans and Notes	$0	$0	$0
Tax-Exempt Bond Liabilities	$0	$0	$0
Other	$0	$0	$0
Total Liabilities	$1,308,675	$2,140,023	$831,348

Fund balance	Jan 01, 2016	Dec 31, 2016	Change
Temporarily Restricted Net Assets	$0	$0	$0
Permanently Restricted Net Assets	$0	$0	$0
Total Restricted Net Assets	$0	$0	$0
Unrestricted Net Assets	$396,145	$308,127	($88,018)
Net Assets	$396,145	$308,127	($88,018)

Assets	Jan 01, 2017	Dec 31, 2017	Change
Contributions	$3,576,806
Cash & Equivalents	$2,168,974	$2,566,468	$397,494
Accounts Receivable	$0	$0	$0
Pledges & Grants Receivable	$262,064	$181,160	($80,904)
Receivable, Other	$0	$0	$0
Inventories for Sale or Use	$0	$0	$0
Investment, Securities	$0	$0	$0
Investment, Other	$0	$0	$0
Fixed Assets (LBE - Depreciation)	$0	$0	$0
Other	$17,112	$57,532	$40,420
Total Assets	$2,448,150	$2,805,160	$357,010

Liabilities	Jan 01, 2017	Dec 31, 2017	Change
Accounts Payable	$2,140,023	$2,522,078	$382,055
Grants Payable	$0	$0	$0
Deferred Revenue	$0	$0	$0
Loans and Notes	$0	$0	$0
Tax-Exempt Bond Liabilities	$0	$0	$0
Other	$0	$0	$0
Total Liabilities	$2,140,023	$2,522,078	$382,055

Fund balance	Jan 01, 2017	Dec 31, 2017	Change
Temporarily Restricted Net Assets	$0	$9,550	$9,550
Permanently Restricted Net Assets	$0	$0	$0
Total Restricted Net Assets	$0	$9,550	$9,550
Unrestricted Net Assets	$308,127	$273,532	($34,595)
Net Assets	$308,127	$283,082	($25,045)

Assets	Jan 01, 2018	Dec 31, 2018	Change
Contributions	$4,241,560
Cash & Equivalents	$2,566,468	$3,151,021	$584,553
Accounts Receivable	$0	$0	$0
Pledges & Grants Receivable	$181,160	$144,219	($36,941)
Receivable, Other	$0	$0	$0
Inventories for Sale or Use	$0	$0	$0
Investment, Securities	$0	$0	$0
Investment, Other	$0	$0	$0
Fixed Assets (LBE - Depreciation)	$0	$0	$0
Other	$57,532	$68,756	$11,224
Total Assets	$2,805,160	$3,363,996	$558,836

Liabilities	Jan 01, 2018	Dec 31, 2018	Change
Accounts Payable	$2,522,078	$3,029,764	$507,686
Grants Payable	$0	$0	$0
Deferred Revenue	$0	$0	$0
Loans and Notes	$0	$0	$0
Tax-Exempt Bond Liabilities	$0	$0	$0
Other	$0	$0	$0
Total Liabilities	$2,522,078	$3,029,764	$507,686

Curebound

Financial trends analysis Glossary & formula definitions

Fiscal Year: Jan 01 - Dec 31

SOURCE: IRS Form 990 info

This snapshot of Curebound’s financial trends applies Nonprofit Finance Fund® analysis to data hosted by GuideStar. While it highlights the data that matter most, remember that context is key – numbers only tell part of any story.

Created in partnership with

Fiscal year: Jan 01 - Dec 31 View full report Download data

Business model indicators

Profitability	2019	2020	2021	2022	2023
Unrestricted surplus (deficit) before depreciation	-$50,121	$510,179	-$426,420	$6,847,535	$1,249,598
As % of expenses	-1.1%	59.8%	-15.2%	111.2%	10.0%
Unrestricted surplus (deficit) after depreciation	-$68,590	$490,847	-$449,965	$6,775,799	$1,226,387
As % of expenses	-1.5%	56.3%	-15.9%	108.8%	9.8%

Revenue composition
Total revenue (unrestricted & restricted)	$4,556,994	$1,362,913	$8,784,431	$19,804,413	$10,395,528
Total revenue, % change over prior year	3.1%	-70.1%	544.5%	125.4%	-47.5%
Program services revenue	6.2%	0.0%	0.9%	14.8%	0.0%
Membership dues	0.0%	0.0%	0.0%	0.0%	0.0%
Investment income	0.0%	0.0%	0.0%	0.0%	2.4%
Government grants	0.0%	0.0%	0.9%	0.0%	0.0%
All other grants and contributions	93.5%	100.0%	98.2%	85.2%	97.7%
Other revenue	0.3%	0.0%	0.0%	0.0%	0.0%

Expense composition
Total expenses before depreciation	$4,607,115	$852,734	$2,810,060	$6,157,333	$12,477,131
Total expenses, % change over prior year	5.9%	-81.5%	229.5%	119.1%	102.6%
Personnel	12.1%	55.8%	17.2%	18.7%	6.1%
Professional fees	1.7%	10.1%	8.7%	17.4%	13.7%
Occupancy	1.4%	7.4%	1.2%	0.1%	0.7%
Interest	0.0%	0.0%	0.6%	0.0%	0.0%
Pass-through	67.9%	0.0%	54.3%	48.7%	67.3%
All other expenses	16.9%	26.7%	18.0%	15.1%	12.3%

Full cost components (estimated)	2019	2020	2021	2022	2023
Total expenses (after depreciation)	$4,625,584	$872,066	$2,833,605	$6,229,069	$12,500,342
One month of savings	$383,926	$71,061	$234,172	$513,111	$1,039,761
Debt principal payment	$0	$0	$76,995	$0	$0
Fixed asset additions	$0	$0	$0	$0	$0
Total full costs (estimated)	$5,009,510	$943,127	$3,144,772	$6,742,180	$13,540,103

Capital structure indicators

Liquidity	2019	2020	2021	2022	2023
Months of cash	8.5	9.6	11.0	20.1	13.1
Months of cash and investments	8.5	9.6	11.0	20.1	13.1
Months of estimated liquid unrestricted net assets	0.7	10.6	1.3	13.8	8.0

Balance sheet composition	2019	2020	2021	2022	2023
Cash	$3,254,098	$682,767	$2,567,562	$10,319,720	$13,663,004
Investments	$0	$0	$0	$0	$0
Receivables	$142,230	$135,490	$4,923,589	$13,044,813	$10,521,177
Gross land, buildings, equipment (LBE)	$0	$0	$0	$0	$0
Accumulated depreciation (as a % of LBE)	0.0%	0.0%	0.0%	0.0%	0.0%
Liabilities (as a % of assets)	92.4%	14.0%	11.8%	14.0%	25.5%
Unrestricted net assets	$265,642	$756,489	$306,524	$7,082,323	$8,308,710
Temporarily restricted net assets	N/A	N/A	N/A	N/A	N/A
Permanently restricted net assets	N/A	N/A	N/A	N/A	N/A
Total restricted net assets	$0	$0	$6,400,791	$13,201,698	$9,870,497
Total net assets	$265,642	$756,489	$6,707,315	$20,284,021	$18,179,207

Key data checks

Key data checks	2019	2020	2021	2022	2023
Material data errors	No	No	No	No	No

Operations

The people, governance practices, and partners that make the organization tick.

Documents

Letter of Determination

Form 1023/1024 is not available for this organization

CEO

Anne Marbarger

LinkedIn profile

Anne Marbarger is the CEO of Curebound. With her eyes set on significantly growing the organization, Anne is responsible for building a community of sponsors, riders, fundraisers and passionate cancer warriors in support of the organization's mission to fund the best collaborative cancer research in San Diego. Anne began working with Pedal the Cause in 2015 as Director of Programs and was promoted to lead the organization the following year.

Number of employees

Source: IRS Form 990

Curebound

Officers, directors, trustees, and key employees

SOURCE: IRS Form 990

Compensation

Other

Show data for fiscal year

Compensation data

Download up to 5 most recent years of officer and director compensation data for this organization

Curebound

Highest paid employees

SOURCE: IRS Form 990

Compensation

Other

Show data for fiscal year

Compensation data

Download up to 5 most recent years of highest paid employee data for this organization

Curebound

Board of directors
as of 5/5/2025

SOURCE: Self-reported by organization

Board of directors data

Download the most recent year of board of directors data for this organization

Board chair

William Koman

Aaron Davis Director

Aaron Davis

Boxer Capital

Anne Marbarger CEO

Cat Jamieson Director

Catriona Jamieson

UC San Diego

Cheryl Anderson

Cheryl Anderson Director

Chris Tresse Secretary

Christian Tresse

Bernstein Private Wealth Management

Court Turner Director

Daniel Ryan Director

Daniel Ryan

Alexandria Real Estate Equities

Don Ankeny Treasurer

Donald Ankeny

Westcore

Donald Kearns

Donald Kearns Director

Fernanda Whitworth

Fernanda Whitworth Director

John Hood Director

John Hood

Endeavor Biomedicines

Julie Klaus

Larry Bloch

Larry Bloch Director

Magda Marquet

Magda Marquet Director

Malin Burnham Director

Mark Cafferty

San Diego Regional Economic Development Co

Mark Cafferty Director

Rich Heyman Director

Rich Heyman

ARCH Venture Partners

Rob Singh

CONAM

Rob Singh Director

Robin Toft

William Koman Chairman

William Koman

Board leadership practices

SOURCE: Self-reported by organization

GuideStar worked with BoardSource, the national leader in nonprofit board leadership and governance, to create this section.

Board orientation and education
Does the board conduct a formal orientation for new board members and require all board members to sign a written agreement regarding their roles, responsibilities, and expectations? no
CEO oversight
Has the board conducted a formal, written assessment of the chief executive within the past year ? yes
Ethics and transparency
Have the board and senior staff reviewed the conflict-of-interest policy and completed and signed disclosure statements in the past year? no
Board composition
Does the board ensure an inclusive board member recruitment process that results in diversity of thought and leadership? yes
Board performance
Has the board conducted a formal, written self-assessment of its performance within the past three years? no

Organizational demographics

Candid has made improvements to the race and ethnicity options.

Who works and leads organizations that serve our diverse communities? Candid partnered with CHANGE Philanthropy on this demographic section.

Leadership

The organization's leader identifies as:

Race & ethnicity

White/Caucasian/European

Gender identity

Female

Disability status

Person without a disability

Race & ethnicity

Gender identity

Transgender Identity

Sexual orientation

Disability

Contractors

Fiscal year ending

There are no fundraisers recorded for this organization.

Curebound

Accelerating Cancer Cures

Mission

Is this your nonprofit?

Programs and results

Reports and documents

What we aim to solve

Our programs

Discovery Grants

Targeted Grants

Cure Prize

Where we work

Awards

Our results

Evaluation documents

Total dollar amount of grants awarded

Totals By Year

Population(s) Served

Related Program

Type of Metric

Direction of Success

Context Notes

Goals & Strategy

Charting impact

What is the organization aiming to accomplish?

What are the organization's key strategies for making this happen?

What are the organization's capabilities for doing this?

What have they accomplished so far and what's next?

How we listen

Financials

Financial documents

Revenue vs. expenses: breakdown

Liquidity in 2023 info

2.20

Months of cash in 2023 info

13.1

Fringe rate in 2023 info

0%

Funding sources info

Assets & liabilities info

Financial data

Digitizing IRS form 990 data

Curebound

Curebound

Curebound

Business model indicators

Capital structure indicators

Key data checks

Operations

Documents

CEO

Anne Marbarger

Number of employees

Curebound

Compensation data

Curebound

Compensation data

Curebound

Board of directors data

William Koman

Board leadership practices

Board orientation and education

CEO oversight

Ethics and transparency

Board composition

Board performance

Organizational demographics

Leadership

Race & ethnicity

Gender identity

Transgender Identity

Sexual orientation

Disability

Contractors

Liquidity in 2023

Months of cash in 2023

Fringe rate in 2023

Funding sources

Assets & liabilities